Blueprint Medicines is a precision therapy company that is inventing medicines for people with cancer and hematologic disorders. Co. is developing programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy including: AYVAKIT/AYVAKYT® (avapritinib), which is for the treatment of systemic mastocytosis (SM); BLU-263, which is for the treatment of non-advanced SM and other mast cell disorders; GAVRETO (pralsetinib), which is for the treatment of RET fusion-positive non-small cell lung cancer, and for the treatment of RET-altered thyroid carcinoma, including medullary thyroid carcinoma; and fisogatinib, which is for the treatment of hepatocellular carcinoma. The BPMC stock yearly return is shown above.
The yearly return on the BPMC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BPMC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|